本帖最后由 老马 于 2013-3-13 13:43 编辑 ! c2 y5 V G- a9 D! D% K
5 Y0 |% H( o; y& S6 {( Y
健择（吉西他滨）+顺铂+阿瓦斯汀
: }. v: C" H1 u Gemzar +Cisplatin + Avastin- g. _2 Y g; e4 D
http://annonc.oxfordjournals.org/content/21/9/1804.full
6 Q& E* C5 M) D- E4 aOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
0 i2 `) ]1 ^: V; A! v; |Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. 7 N) K ~+ E* Z( P) a5 }
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
L5 u/ _% o5 ?" C v1 _' F( t: k
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 1028)
' g$ s5 [- p1 c3 [3 y( Z华为网盘附件：$ T$ o' ^- e9 P' V
【华为网盘】ava.JPG
1 o& H( B7 `$ H |
显身卡
